Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

19q13-ERCC1 gene copy number increase in non--small-cell lung cancer.

Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, Goubar A, Li Y, Robin A, Behrens C, Commo F, Validire P, André F, Wistuba II, Soria JC, Olaussen KA.

Clin Lung Cancer. 2013 Sep;14(5):549-57. doi: 10.1016/j.cllc.2013.01.006. Epub 2013 Jun 15.

PMID:
23773262
2.

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC.

N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271.

3.

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.

Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC.

Lung Cancer. 2013 May;80(2):216-22. doi: 10.1016/j.lungcan.2013.01.014. Epub 2013 Feb 12.

PMID:
23410825
4.

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.

Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC.

Nat Rev Clin Oncol. 2012 Feb 14;9(3):144-55. doi: 10.1038/nrclinonc.2012.3. Review.

PMID:
22330686
5.

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV.

Sci Transl Med. 2011 Jun 1;3(85):85ra47. doi: 10.1126/scitranslmed.3002004.

6.

Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival.

Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X, Hondermarck H.

Clin Cancer Res. 2011 Apr 1;17(7):1741-52. doi: 10.1158/1078-0432.CCR-10-1890. Epub 2011 Feb 24.

7.

Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1.

Ndour PA, Ouk TS, Brocqueville G, Mougel A, Vanhecke E, Feuillard J, Coll J, Adriaenssens E.

Cell Signal. 2010 Feb;22(2):303-13. doi: 10.1016/j.cellsig.2009.09.037. Epub 2009 Sep 29.

PMID:
19796681
8.

TrkA overexpression enhances growth and metastasis of breast cancer cells.

Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X.

Oncogene. 2009 May 7;28(18):1960-70. doi: 10.1038/onc.2009.61. Epub 2009 Mar 30.

PMID:
19330021
9.

Nerve growth factor is a potential therapeutic target in breast cancer.

Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H.

Cancer Res. 2008 Jan 15;68(2):346-51. doi: 10.1158/0008-5472.CAN-07-1183.

10.

An epidemic of allergic contact dermatitis due to epilating products.

Goossens A, Armingaud P, Avenel-Audran M, Begon-Bagdassarian I, Constandt L, Giordano-Labadie F, Girardin P, Coz CJ, Milpied-Homsi B, Nootens C, Pecquet C, Tennstedt D, Vanhecke E.

Contact Dermatitis. 2002 Aug;47(2):67-70.

PMID:
12423402

Supplemental Content

Loading ...
Support Center